Methods: Thirty subjects with neurodegenerative cognitive disorders (10 with Alzheimer’s Disease, 10 with Frontotemporal Dementia, and 10 with non-progressive Mild Cognitive Impairment) seen at the Cognitive Neurology Clinic of Modena University Hospital (Italy) underwent CSF and serum NfL measurement with both the EllaTM microfluidic platform (Bio-Techne, Minneapolis, MN, USA)) and the LumipulseTM fully automated system for the CLEIA (Fujirebio Inc., Ghent, Belgium). Here, NEFL is linked to early-onset autosomal dominant Alzheimer disease.